Business context and reporting period
Radiopharm Theranostics Limited filed this Form 6-K as a foreign private issuer for October 2026. The report, dated October 1, 2026, attaches two announcements published to the Australian Securities Exchange on that date.
Financial results and key metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics.
Material changes
- Exhibit 99.1 is titled “Change of Director’s Interest Notice (RC).”
- Exhibit 99.2 is titled “Notification of cessation of securities - RAD.”
The filing text does not provide the details or quantities underlying either announcement.
Guidance, risks, and unusual items
No guidance, outlook, management commentary, risks, or contingencies are described in the filing text. The report states that it is not deemed filed for purposes of the Securities Exchange Act of 1934 and is not incorporated by reference into registration statements or prospectuses unless specifically referenced.
Important facts to verify
- Review the attached director interest notice for the nature, timing, and extent of the reported change.
- Review the cessation-of-securities notice for the securities affected, quantities, and reason for cessation.